Other languages FluoGuide A/S

Equities

FLUO

DK0061123312

Delayed Nasdaq Stockholm Other stock markets 08:41:36 2024-04-24 am EDT			5-day change	1st Jan Change
44.9 ^SEK	+2.28%		+0.79%	-26.63%

Mar. 20	FluoGuide A/S Approves Board Changes	CI
Mar. 12	FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FluoGuide A/S Approves Board Changes	Mar. 20
FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc	Mar. 12
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001	Jan. 08
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29
FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer	Nov. 13
FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference	Nov. 06
Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague	23-09-07
FluoGuide A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30
Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer	23-08-28
FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer	23-06-20
Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer	23-06-07
FluoGuide A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31
FluoGuide A/S Appoints Michael Thyrring Engsig as Member of the Board of Directors	23-03-21
FluoGuide A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
FluoGuide A/S Updates on Recruitment in Phase IIb Aggressive Brain Cancer Trial with FG001	23-02-27
Sweden's FluoGuide Names Successor as CFO Resigns	23-02-02
FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer	23-01-09
FluoGuide A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24
FluoGuide Enrolls First Patient for Technology Platform Study in Head, Neck Cancer	22-11-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages FluoGuide A/S

Equities

FLUO

DK0061123312

Other languages

Filters